Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Minter

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Communications Biology|September 19, 2024
Targeted protein degradation using chimeric human E2 ubiquitin-conjugating enzymesJonathan D Taylor, Nathalie Barrett, Sergio Martinez Cuesta, et al.
British Journal of Pharmacology|August 24, 2012
Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritisR R Minter, E S Cohen, B Wang, et al.
Leukemia & Lymphoma|December 23, 2015
Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imagingManisha Bhutani, Baris Turkbey, Esther Tan, et al.
Leukemia|September 19, 2013
Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trialM Bhutani, B Turkbey, E Tan, et al.
Arthritis and Rheumatism|November 13, 2003
Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulatorKevin P Baker, Bryan M Edwards, Sarah H Main, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 25, 2016
A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn BindingJulie Douthwaite, Jacques Moisan, Cyril Privezentzev, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 23, 2017
Correction: A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn BindingJulie Douthwaite, Jacques Moisan, Cyril Privezentzev, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Communications Biology|September 19, 2024
Targeted protein degradation using chimeric human E2 ubiquitin-conjugating enzymesJonathan D Taylor, Nathalie Barrett, Sergio Martinez Cuesta, et al.
British Journal of Pharmacology|August 24, 2012
Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritisR R Minter, E S Cohen, B Wang, et al.
Leukemia & Lymphoma|December 23, 2015
Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imagingManisha Bhutani, Baris Turkbey, Esther Tan, et al.
Leukemia|September 19, 2013
Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trialM Bhutani, B Turkbey, E Tan, et al.
Arthritis and Rheumatism|November 13, 2003
Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulatorKevin P Baker, Bryan M Edwards, Sarah H Main, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 25, 2016
A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn BindingJulie Douthwaite, Jacques Moisan, Cyril Privezentzev, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 23, 2017
Correction: A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn BindingJulie Douthwaite, Jacques Moisan, Cyril Privezentzev, et al.
Pageof 6